Home › Funds › Logos Global Management LP › AVTX
Logos Global Management LP position in AVTX
AVALO THERAPEUTICS INC · Health Care
Logos Global Management LP reported holding 1,150,000 shares of AVTX (AVALO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$21.3M, representing 0.91% of its reported portfolio and ranking #34 among its reported holdings. Logos Global Management LP has disclosed AVTX holdings in 4 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Logos Global Management LP's AVTX position evolved
Logos Global Management LP first disclosed a stake in AVTX in Q2 2024 at 539,079 shares (US$6.7M). The position peaked in Q2 2026 at 1,150,000 shares, worth US$21.3M. Across 4 filings, Logos Global Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,150,000 shares valued at US$21.3M — an increase of 850,000 shares quarter over quarter.. Notable position changes include a 283% increase in Q2 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 539.08K | $6.72M | New |
| Q3 2024 | 539.08K | $5.12M | Hold |
| Q1 2026 | 300.00K | $4.48M | New |
| Q2 2026 | 1.15M | $21.25M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVTX and 13F data
AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 83 other funds we track also report a position in AVTX — the largest reported positions include Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVTX
- Deep Track Capital, LP 3.61M sh · $66.71M · Q2 2026
- Caligan Partners LP 3.16M sh · $58.47M · Q2 2026
- TCG Crossover Management, LLC 3.02M sh · $55.76M · Q2 2026
- Affinity Asset Advisors, LLC 2.90M sh · $53.59M · Q2 2026
- Farallon Capital Management 2.50M sh · $46.16M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.33M sh · $43.12M · Q2 2026
- BVF INC/IL 2.08M sh · $38.36M · Q2 2026
- Nantahala Capital Management, LLC 1.86M sh · $34.41M · Q2 2026
- Soleus Capital Management, L.P. 1.65M sh · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M sh · $30.11M · Q2 2026
- Commodore Capital LP 1.02M sh · $18.82M · Q2 2026
More on Logos Global Management LP
FAQ
How long has Logos Global Management LP held AVTX?
Logos Global Management LP has disclosed AVTX holdings in 4 of the last 9 reported quarters, going back to Q2 2024.
What is Logos Global Management LP's current position in AVTX?
As of Q2 2026, Logos Global Management LP holds 1.15M shares of AVTX (AVALO THERAPEUTICS INC), valued at $21.25M, representing 0.91% of its reported portfolio and ranking #34.
Has Logos Global Management LP been buying or selling AVTX?
In the latest 13F filing (Q2 2026), Logos Global Management LP increased its position in AVTX. The position peaked in Q2 2026 at 1.15M shares.
Which other funds hold AVTX?
Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.